Physician profile
Joseph Malak
NPI 1497723878
$1,071.39
in general payments reported to CMS, 2019-2025
12 companies · $98.77 in 2025
The $98.77 reported for 2025 was less than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $122 · 2021: $124 · 2022: $216 · 2023: $149 · 2024: $116 · 2025: $98.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $364.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $329.01 | 2021-2024 | Auvi-Q |
| Pfizer INC. | $208.80 | 2019-2025 | |
| Sobi, INC | $193.56 | 2019-2023 | |
| Glaxosmithkline, LLC. | $98.30 | 2019-2024 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $55.37 | 2020 | |
| Merck Sharp & Dohme LLC | $48.50 | 2022-2023 | M-M-R II, Vaxneuvance, Rotateq |
| Astrazeneca Pharmaceuticals Lp | $38.12 | 2024-2025 | Fasenra |
| Cumberland Pharmaceuticals, INC. | $30.17 | 2023 | Kristalose |
| Genzyme Corporation | $19.79 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $18.34 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $17.45 | 2024 | |
| Cranial Technologies, INC | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Malak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.